Artificial Intelligence and Amikacin Exposures Predictive of Outcomes in Multidrug-Resistant Tuberculosis Patients

Aminoglycosides such as amikacin continue to be part of the backbone of treatment of multidrug-resistant tuberculosis (MDR-TB). We measured amikacin concentrations in 28 MDR-TB patients in Botswana receiving amikacin therapy together with oral levofloxacin, ethionamide, cycloserine, and pyrazinamide...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:Antimicrob Agents Chemother
Hoofdauteurs: Modongo, Chawangwa, Pasipanodya, Jotam G., Magazi, Beki T., Srivastava, Shashikant, Zetola, Nicola M., Williams, Scott M., Sirugo, Giorgio, Gumbo, Tawanda
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: American Society for Microbiology 2016
Onderwerpen:
Experimental Therapeutics
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5038293/
https://ncbi.nlm.nih.gov/pubmed/27458224
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.00962-16
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items